全文获取类型
收费全文 | 12480篇 |
免费 | 1201篇 |
国内免费 | 451篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 57篇 |
妇产科学 | 21篇 |
基础医学 | 282篇 |
口腔科学 | 21篇 |
临床医学 | 1534篇 |
内科学 | 5581篇 |
皮肤病学 | 48篇 |
神经病学 | 158篇 |
特种医学 | 736篇 |
外国民族医学 | 1篇 |
外科学 | 1964篇 |
综合类 | 2044篇 |
现状与发展 | 1篇 |
预防医学 | 262篇 |
眼科学 | 4篇 |
药学 | 859篇 |
13篇 | |
中国医学 | 321篇 |
肿瘤学 | 194篇 |
出版年
2024年 | 15篇 |
2023年 | 291篇 |
2022年 | 349篇 |
2021年 | 795篇 |
2020年 | 693篇 |
2019年 | 596篇 |
2018年 | 623篇 |
2017年 | 494篇 |
2016年 | 540篇 |
2015年 | 568篇 |
2014年 | 960篇 |
2013年 | 959篇 |
2012年 | 895篇 |
2011年 | 917篇 |
2010年 | 733篇 |
2009年 | 655篇 |
2008年 | 617篇 |
2007年 | 643篇 |
2006年 | 466篇 |
2005年 | 380篇 |
2004年 | 301篇 |
2003年 | 238篇 |
2002年 | 217篇 |
2001年 | 156篇 |
2000年 | 138篇 |
1999年 | 127篇 |
1998年 | 107篇 |
1997年 | 81篇 |
1996年 | 61篇 |
1995年 | 80篇 |
1994年 | 78篇 |
1993年 | 55篇 |
1992年 | 48篇 |
1991年 | 48篇 |
1990年 | 36篇 |
1989年 | 31篇 |
1988年 | 25篇 |
1987年 | 19篇 |
1986年 | 18篇 |
1985年 | 26篇 |
1984年 | 15篇 |
1983年 | 5篇 |
1982年 | 14篇 |
1981年 | 5篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 5篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
目的探讨经皮椎体后凸成形术(PKP)术中不同注入量高粘度骨水泥治疗骨质疏松性腰椎骨折(OLVF)的疗效及安全性。 方法前瞻性收集2016年9月至2018年9月本院OLVF患者150例,男84例,女66例,年龄(60±8)岁。依据随机数字表分为高量组、中量组、低量组,每组50例,高量组、中量组、低量组PKP术中高粘度骨水泥注入量分别为5.0~7.0 ml、3~4.9 ml、<3.0 ml,比较三组疗效及安全性。 结果150例患者获得满意随访,随访时间(19±7)个月。高量组、中量组、低量组手术时间、术中出血量比较,差异无统计学意义(P>0.05);高量组和中量组术后3、6个月椎体前缘高度[(27.3±3.1)mm、(26.0±2.7)mm和(26.9±3.0)mm、(25.7±2.8)mm]明显高于低量组[(23.8±2.8)mm、(21.3±2.5)mm],高量组和中量组术后3、6个月Cobb角及疼痛视觉模拟评分法(VAS)、Oswestry功能障碍指数问卷表(ODI)评分[(40.2±4.7)°、(41.5±4.8)°、(2.6±0.4)分、(1.6±0.3)分、(25.8±3.5)分、(26.9±3.5)分和(40.9±4.8)°、(42.1±4.8)°、(2.6±0.4)分、(1.6±0.3)分、(26.2±3.5)分、(27.2±3.7)分]明显低于低量组[(46.3±5.3)°、(47.8±5.6)°、(3.3±0.4)分、(2.3±0.4)分、(33.3±4.1)分、(34.3±4.2)分],差异有统计学意义(F=25.371、18.914、29.334、22.457、34.276、30.217、29.364、20.071,均P<0.001);高量组骨水泥渗漏率(28.00%)明显高于中量组和低量组(8.00%和4.00%),差异有统计学意义(χ2=10.241,P=0.005)。 结论PKP术中不同注入量高粘度骨水泥治疗OLVF的疗效及安全性存在一定的差异,其中注入中量(3~4.9 ml)高粘度骨水泥可获得良好的疗效及安全性,值得临床推广。 相似文献
3.
《Journal of vascular and interventional radiology : JVIR》2022,33(8):895-902.e4
PurposeTo study, from a U.S. payer’s perspective, the economic consequences of drug-coated balloon (DCB) versus standard percutaneous transluminal angioplasty (PTA) use for the treatment of stenotic lesions in dysfunctional hemodialysis arteriovenous fistulae.Materials and MethodsCost differences between DCBs and PTA at year 1 and beyond were calculated via 2 methods. The first approach used the mean absolute number of trial-observed access circuit reinterventions through 12 months (0.65 ± 1.05 vs 1.05 ± 1.18 events per patient for DCBs and PTA, respectively) and projected treatment outcomes to 3 years. The second approach was based on the trial-observed access circuit primary patency rates at 12 months (53.8% vs 32.4%) and calculated the cost difference on the basis of previously published Medicare cost for patients who maintained or did not maintain primary patency. Assumptions regarding DCB device prices were tested in sensitivity analyses, and the numbers needed to treat were calculated.ResultsUsing the absolute number of access circuit reinterventions approach, the DCB strategy resulted in an estimated per-patient savings of $1,632 at 1 year and $4,263 at 3 years before considering the DCB device cost. The access circuit primary patency approach was associated with a per-patient cost savings of $2,152 at 1 year and $3,894 at 2.5 years of follow-up. At the theoretical DCB device reimbursement of $1,800, savings were $1,680 and $2,049 at 2.5 and 3 years, respectively. The one-year NNT of DCB compared to PTA was 2.48.ConclusionsEndovascular therapy for arteriovenous access stenosis with the IN.PACT AV DCB can be expected to be cost-saving if longer follow-up data confirm its clinical effectiveness. 相似文献
4.
《Journal of vascular and interventional radiology : JVIR》2022,33(10):1143-1150
PurposeTo report the 5-year results from the Pivotal Multicenter Trial of Ultrasound-Guided Percutaneous Arteriovenous Fistula (pAVF) Creation for Hemodialysis Access.Materials and MethodsThe retrospective review of 107 intent-to-treat (ITT) patients from the pivotal trial provided a long-term follow-up population (LTP) of 85 patients with a median follow-up duration of 50 months (range, 12–60 months). Data evaluated in the LTP group were fistula maturation and usage, secondary procedures, and complications. The Kaplan-Meier analysis of primary patency, assisted primary patency, cumulative patency, and functional patency (time from 2-needle cannulation to abandonment) were performed for the ITT population.ResultsIn the LTP, 99% (84 of 85) of fistulae were mature, with 99% (78 of 79) of patients requiring hemodialysis using their pAVF. Sustained fistula use (2-needle cannulation at the prescribed rate, 2 of 3 sessions) was achieved in 92% (78 of 85) of patients, with 7 patients not using their pAVF because they were not on dialysis (n = 4), were on peritoneal dialysis (n = 2), and refused to use fistula (n = 1). Fistula maintenance was required in 31.8% (27 of 85) of patients and included fistula dysfunction (21.2%), thrombosis (5.9%), cannulation injury (12.9%), and arm swelling (4.7%). The number of procedures performed per patient per year to maintain function and patency was 0.32 (91 of 288) for years 2–5. The cumulative patency rates were 89.5%, 88.4%, 88.4%, 85.6%, and 82.0% for years 1, 2, 3, 4, and 5, respectively. The functional patency was 91.8% at the end of the study. There were no major complications related to pAVF during the long-term follow-up.ConclusionsPercutaneous fistulae have provided clinically effective and durable access for hemodialysis with low complications. The continued use and evaluation of pAVF are warranted. 相似文献
5.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):399-407
PurposeTo evaluate the midterm outcomes of percutaneous transluminal renal angioplasty (PTRA) for pediatric renovascular hypertension (RVH).Materials and MethodsThe clinical data of patients who underwent PTRA for RVH in the authors’ hospital from 2012 to 2019 were retrospectively analyzed. Postprocedural blood pressure, glomerular filtration rate (GFR) of the affected kidney, restenosis, and complications were closely monitored.ResultsPTRA was performed in a total of 30 children (20 boys and 10 girls), with a mean age of 7.3 years ± 0.7 (range, 40 days to 13.9 years) and a mean weight of 25.0 kg ± 2.3 (range, 3.4–53 kg). The median follow-up period was 26.5 months (range, 1 month to 7.5 years). Technical success was achieved in 26 (86.7%) of the 30 patients. Restenosis developed in 3 patients (10.0%). Only 1 patient underwent stent implantation, and the stent fractured 8 months later, requiring further intervention. There were no other complications. In terms of clinical benefit of blood pressure control after the initial PTRA procedure, 15 patients (50%) were cured and 7 patients (23.3%) showed improvement. There was no significant difference in the etiology, lesion location, and lesion length between patients with clinical benefit and failure (P = .06, P = .202, and P = .06, respectively). GFR of the affected kidney was significantly improved from 19.9 mL/min ± 11.2 to 38.1 mL/min ± 11.9 at the 6-month follow-up after PTRA (P < .001).ConclusionsThe overall results of PTRA for pediatric RVH caused by different etiologies are promising. PTRA not only provided a clinical benefit of blood pressure control in 73.3% of the patients but also significantly improved the function of the affected kidney. 相似文献
6.
目的:探讨经皮冠状动脉介入(PCI)术后病人的体力活动水平及其影响因素。方法:选择常州市三级甲等综合医院心内科接受PCI治疗的冠心病病人,收集资料,分析PCI术后冠心病病人体力活动动机、体力活动和自我效能现状;冠心病病人自我效能、体力活动动机与体力活动的相关性,并分析影响PCI术后病人体力活动水平的相关危险因素。结果:共发放调查问卷400份,回收400份,有效率为94.75%(379/400);379例冠心病病人术后每周体力活动为(3570.85±314.19)MET-min,以低、中强度为主;冠心病病人术后自我效能总分、体力活动动机总分与体力活动呈正相关(P<0.05);体质指数(BMI)、PCI次数≥2次、年龄、PCI支架数量≥3枚、自我效能、体力活动动机是影响PCI术后冠心病病人体力活动水平的高危因素(OR>1且P<0.05)。结论:PCI术后病人体力活动水平处于较低的水平,PCI次数、BMI、年龄、PCI支架数量、自我效能、体力活动动机是影响PCI术后冠心病病人体力活动水平的高危因素,临床需针对各高危因素制定相应的干预措施,提高病人体力活动水平。 相似文献
7.
8.
9.
10.